GlassScriptPhysician profile
Milan N Sheth
NPI 1083694707
$57,718.38
in general payments reported to CMS, 2019-2025
30 companies · $1,021 in 2025
The $1,021 reported for 2025 was more than what 85% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48K · 2020: $5,525 · 2021: $107 · 2022: $679 · 2023: $1,116 · 2024: $1,295 · 2025: $1,021.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,331 · Education: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,330.80 |
| Education | $101.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $53,397.60 | 2019-2025 | |
| Novo Nordisk INC | $769.33 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $403.98 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $371.87 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $277.56 | 2022-2025 | Qulipta, Vraylar, Ubrelvy |
| Dexcom, INC. | $247.00 | 2022-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $245.91 | 2022-2025 | |
| Amgen INC. | $213.02 | 2023-2025 | Repatha, Otezla, Repatha |
| Otsuka America Pharmaceutical, INC. | $203.75 | 2023-2025 | Rexulti |
| Lilly USA, LLC | $195.28 | 2020-2025 | Mounjaro, Zepbound, Trulicity |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $158.47 | 2021-2025 | Lifevest |
| Glaxosmithkline, LLC. | $150.96 | 2019-2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Astellas Pharma US INC | $149.61 | 2024-2025 | Veozah |
| Abbott Laboratories | $130.28 | 2023-2025 | Freestyle Libre 3 |
| E.R. Squibb & Sons, L.L.C. | $122.58 | 2019-2024 | Camzyos, Eliquis |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $121.79 | 2023-2025 | Gemtesa |
| Boston Scientific Corporation | $104.02 | 2020-2023 | Watchman Flx |
| Merck Sharp & Dohme LLC | $92.06 | 2022-2023 | Verquvo, Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $87.65 | 2019-2024 | Jardiance |
| Xeris Pharmaceuticals, INC. | $58.08 | 2023-2024 | Gvoke Hypopen |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.32 | 2025 | Caplyta |
| Amarin Pharma, INC. | $28.79 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.38 | 2025 | Xifaxan |
| Daiichi Sankyo INC. | $21.42 | 2023 | Injectafer |
| Axsome Therapeutics, INC. | $19.22 | 2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $18.54 | 2024 | Voquezna |
| Sanofi-Aventis U.S. LLC | $17.46 | 2022 | |
| W. L. Gore & Associates, INC. | $16.33 | 2022 | |
| Exact Sciences Corporation | $16.19 | 2024 | Cologuard Collection Kit |
| Lantheus Medical Imaging, INC. | $15.93 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Milan Sheth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.